Adaptimmune announced clinical progress with partial responses in 4 out of 5 synovial sarcoma patients treated with 10B cells in the ADP-A2M4 pilot study and tumor shrinkage seen in nearly all assessed synovial sarcoma patients. Based on these data, the company will initiate the SPEARHEAD-1 trial in patients with synovial sarcoma and myxoid/round cell liposarcoma, or MRCLS, later this year. Beyond sarcoma, there is evidence of antitumor activity with ADP-A2M4 and ADP-A2M10 in other solid tumors. Based on these data and translational findings, the company is expanding its clinical trial program by initiating a radiation sub-study, as well as opening a next-generation ADP-A2M4CD8 study, for which the IND has been filed. Finally, the first patient with HCC was treated in Cohort 2 of the ADP-A2AFP study and showed tolerability to treatment and a transient decrease in serum AFP as well as tumor shrinkage at first scan. ADP-A2M4 SPEAR T-cells appear to show a favorable benefit:risk profile in patients with synovial sarcoma with “good” tolerability overall. Most adverse events are consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies. Tumor shrinkage seen in lung patients in ADP-A2M10 and melanoma and ovarian patients in ADP-A2M4. Adaptimmune is planning to start two new studies to transform currently observed activity in epithelial tumors into durable responses.
https://thefly.com/landingPageNews.php?id=2903577
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.